IL161774A0 - Nutritional supplements and methods for prevention, reduction and treatment of radiation injury - Google Patents

Nutritional supplements and methods for prevention, reduction and treatment of radiation injury

Info

Publication number
IL161774A0
IL161774A0 IL16177402A IL16177402A IL161774A0 IL 161774 A0 IL161774 A0 IL 161774A0 IL 16177402 A IL16177402 A IL 16177402A IL 16177402 A IL16177402 A IL 16177402A IL 161774 A0 IL161774 A0 IL 161774A0
Authority
IL
Israel
Prior art keywords
prevention
reduction
treatment
methods
nutritional supplements
Prior art date
Application number
IL16177402A
Other languages
English (en)
Original Assignee
The Quigley Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/993,003 external-priority patent/US6753325B2/en
Priority claimed from US10/045,790 external-priority patent/US7435725B2/en
Application filed by The Quigley Corp filed Critical The Quigley Corp
Publication of IL161774A0 publication Critical patent/IL161774A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/254—Acanthopanax or Eleutherococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4986—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with sulfur as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/004—Aftersun preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
IL16177402A 2001-11-06 2002-05-01 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury IL161774A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/993,003 US6753325B2 (en) 2001-11-06 2001-11-06 Composition and method for prevention, reduction and treatment of radiation dermatitis
US10/045,790 US7435725B2 (en) 2001-11-06 2002-01-14 Oral compositions and methods for prevention, reduction and treatment of radiation injury
US10/132,642 US20030105027A1 (en) 2001-11-06 2002-04-25 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
PCT/US2002/013526 WO2003039452A2 (en) 2001-11-06 2002-05-01 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury

Publications (1)

Publication Number Publication Date
IL161774A0 true IL161774A0 (en) 2005-11-20

Family

ID=27366753

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16177402A IL161774A0 (en) 2001-11-06 2002-05-01 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
IL16177502A IL161775A0 (en) 2001-11-06 2002-11-06 Topical compositions and methods for treatment of adverse effects ofionizing radiation

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL16177502A IL161775A0 (en) 2001-11-06 2002-11-06 Topical compositions and methods for treatment of adverse effects ofionizing radiation

Country Status (10)

Country Link
US (1) US20030105027A1 (https=)
EP (2) EP1505984A4 (https=)
JP (2) JP2005510509A (https=)
CN (2) CN1630521A (https=)
AU (2) AU2002309615B2 (https=)
CA (2) CA2465945A1 (https=)
IL (2) IL161774A0 (https=)
MX (2) MXPA04004376A (https=)
NZ (2) NZ532774A (https=)
WO (2) WO2003039452A2 (https=)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352713B1 (en) * 1999-12-01 2002-03-05 Drugtech Corporation Nutritional composition
US7449451B2 (en) * 2001-08-29 2008-11-11 Premier Micronutrient Corporation Use of multiple antioxidant micronutrients as systemic biological radioprotective agents against potential ionizing radiation risks
US6849613B2 (en) 2001-08-29 2005-02-01 Kedar N. Prasad Multiple antioxidant micronutrients
US6896913B2 (en) * 2002-06-04 2005-05-24 East West Medical Research Institute Antihistamine composition
US7919525B2 (en) 2003-02-14 2011-04-05 Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Radiation protection by gamma-tocotrienol
KR101395370B1 (ko) 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
JPWO2005085223A1 (ja) * 2004-03-04 2007-12-13 和夫 永井 骨疾患の予防及び／又は治療用組成物、その組成物を含有する機能性食品もしくは健康食品、並びにその組成物を有効成分とする医薬製剤
KR100868905B1 (ko) * 2004-03-26 2008-11-14 (주)아모레퍼시픽 진세노사이드 ｆ1과 ｅｇｃｇ을 함유한 자외선 조사로유도되는 피부손상 방지용 조성물
US7947645B2 (en) 2004-09-02 2011-05-24 Cognosci, Inc. APO E analogs and methods for their use
JP4864302B2 (ja) * 2004-09-06 2012-02-01 株式会社武蔵野免疫研究所 細胞増殖促進組成物
JP5040060B2 (ja) * 2004-10-14 2012-10-03 大正製薬株式会社 メチオニン配合内服液剤
US8647660B2 (en) 2004-12-29 2014-02-11 Hill's Pet Nutrition, Inc. Combination of limited nutrients and enhanced dietary antioxidants to impart improved kidney health
WO2006089211A2 (en) * 2005-02-17 2006-08-24 Premier Micronutrient Corporation Combat/training antioxidant micronutrient formulation and method of administration
US20060189543A1 (en) * 2005-02-23 2006-08-24 Rosenbloom Richard A Compositions and methods for the treatment of leukemia
JP2006298808A (ja) * 2005-04-19 2006-11-02 Hayashibara Biochem Lab Inc 痛覚刺激緩和剤
AU2006236345B2 (en) * 2005-04-19 2011-03-31 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
CA2654446C (en) 2005-06-07 2014-02-25 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of graft rejection and promotion of graft survival
US9457070B2 (en) 2005-06-07 2016-10-04 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses of alpha 1-antitrypsin for early intervention in bone marrow transplantation and treatment of graft versus host disease
EP2368442B1 (en) 2005-07-27 2014-12-17 Symrise AG Use of hesperetin for enhancing the sweet taste
JP2007091737A (ja) * 2005-09-01 2007-04-12 Chieko Tanaka 口腔用組成物
JP2007223965A (ja) * 2006-02-24 2007-09-06 National Institute Of Advanced Industrial & Technology 表皮角化細胞エンドセリン−１産生抑制剤
US20090068166A1 (en) * 2006-03-17 2009-03-12 Ning Man Cheng Method and composition for protection against radiation
EP3173068B1 (en) * 2006-05-02 2020-09-09 University of Miami Topical co-enzyme q10 formulations and treatment of wounds
GB0614353D0 (en) 2006-07-20 2006-08-30 Oraldent Ltd Oral compositions, their preparation and use
EP1882473A1 (en) * 2006-07-28 2008-01-30 Indena S.P.A. Use of anthocyanosides to prepare formulations for the treatment of mucositis induced by antitumoral drugs
JP4790561B2 (ja) * 2006-10-12 2011-10-12 東洋精糖株式会社 フラボノイド組成物、その製造方法および用途
WO2009002425A2 (en) * 2007-06-22 2008-12-31 Scidose Llc Solubilized formulation of docetaxel without tween 80
WO2009080842A1 (es) * 2007-12-21 2009-07-02 Asac Compañía De Biotecnología E Investigación Sa Composiciones fotoprotectoras
RU2491084C2 (ru) 2007-12-21 2013-08-27 Асак Компанья Де Биотекнолохия Э Инвестигасион, С.А. Способ улучшения терапевтической эффективности куркуминоидов и их аналогов
MX2010011032A (es) 2008-04-11 2011-03-01 Cytotech Labs Llc Star Metodos y uso de induccion de apoptosis en celulas cancerigenas.
CA2744388A1 (en) * 2008-11-21 2010-05-27 The Johns Hopkins University Compositions and methods for treating or preventing radiation injury
IT1398507B1 (it) * 2009-01-13 2013-03-01 Giellepi Chemicals S P A Composizione per il trattamento di neuropatie
CA2751511C (en) 2009-02-23 2017-04-11 Unilever Plc Edible composition for treating cutaneous signs of ageing
CN101524341B (zh) * 2009-03-20 2011-04-20 中国科学院近代物理研究所 异甘草素在制备肿瘤放射治疗辅助治疗药物中的应用
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
US20120219511A1 (en) * 2009-09-29 2012-08-30 Igor Arturovich Petropavlov Oral care compositions containing human recombinant interleukin-1
KR101791277B1 (ko) * 2009-10-20 2017-10-27 디스커버리 파트너스, 엘엘씨 피부과학 및 미용학적 조성물
CN101953506B (zh) * 2010-05-28 2012-12-05 西南大学 β-葡聚糖-茶多酚复合物及其应用
KR101021835B1 (ko) 2010-09-06 2011-03-17 충남대학교산학협력단 크리소스플레놀 시를 함유하는 심장 질환의 예방 및 치료용 조성물
CN102078312A (zh) * 2010-12-24 2011-06-01 中国药科大学 一种姜黄素类化合物干粉吸入剂及其制备方法和用途
US20120183587A1 (en) * 2011-01-18 2012-07-19 Mitsunori Ono Flavonol compositions
US8980574B2 (en) 2011-03-11 2015-03-17 James D. Crapo Method for ameliorating radiation exposure effects with alpha-1 antitrypsin
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
JP5985637B2 (ja) * 2011-08-11 2016-09-06 スティーフェル リサーチ オーストラリア ピーティーワイ リミテッド 抗酸化剤局所用組成物
KR101950661B1 (ko) * 2011-09-28 2019-02-20 라이온 가부시키가이샤 구강용 조성물
US20130164228A1 (en) * 2011-12-21 2013-06-27 Colgate-Palmolive Company Compositions comprising gallates and gallamides
EP2700413B1 (en) 2012-08-20 2015-10-14 Bionoox Suisse SA Composition comprising dihydroquercetin, alpha-tocopherol and bisabolol
CZ306439B6 (cs) * 2012-12-20 2017-01-25 Navrátil Jiří Potravinový doplněk kompenzující nepříznivé účinky očkování
WO2014113635A1 (en) * 2013-01-18 2014-07-24 Sloan-Kettering Institute For Cancer Research Reduction of toxicities by synthetic panaxytriol analogs
US20140274965A1 (en) * 2013-03-14 2014-09-18 Hygia Pharmaceuticals, Llc Drink Product and Use Thereof
US20140274966A1 (en) * 2013-03-14 2014-09-18 Hygia Pharmaceuticals, Llc Drink Product Containing Genistein and Use Thereof
NZ713868A (en) 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
JP6175048B2 (ja) * 2013-12-27 2017-08-02 花王株式会社 容器詰飲料
EP2907513A1 (en) 2014-02-18 2015-08-19 Bionoox Suisse SA Compositions comprising dihydroquercetin for use in methods for alleviating the effects associated with skin inflammatory disorders
EP2952104A1 (en) * 2014-06-05 2015-12-09 Böhm, Kirsten Composition and method for preventing damage of human cells by ionising radiation
US10499682B2 (en) 2014-08-25 2019-12-10 New Age Beverage Corporation Micronutrient formulation in electronic cigarettes
CN104522646A (zh) * 2014-12-18 2015-04-22 无限极（中国）有限公司 一种具有增强免疫力、缓解体力疲劳功能的组合物及其应用
JP2018507895A (ja) 2015-03-18 2018-03-22 バイオヌークス スイス エスエー ヘルペスを処置するための方法において使用するためのジヒドロケルセチンを含む組成物
TWI555537B (zh) * 2015-05-21 2016-11-01 張德生 3’-羥基染料木黃酮用於製備抑制黑色素生成之組合物的用途
WO2017030167A1 (ja) * 2015-08-18 2017-02-23 レジリオ株式会社 神経回路網の再構築・賦活剤
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
CN105497006A (zh) * 2015-12-15 2016-04-20 武汉华纳联合药业有限公司 黄酮醇、黄烷醇类化合物的用途
US10183026B2 (en) * 2016-04-08 2019-01-22 The Secretary, Department Of Atomic Energy Method of adjuvant treatment with chlorophyllin containing therapeutic preparation including for radioprotection of normal tissues during radiation therapy and kit therefor
US20190183908A1 (en) * 2016-05-13 2019-06-20 Case Western Reserve University Autophagy activators for treating or preventing skin injury
ES3017696T3 (en) 2017-05-17 2025-05-13 Bpgbio Inc Use of coenzyme q10 formulations in the treatment and prevention of epidermolysis bullosa
KR102288921B1 (ko) * 2018-05-28 2021-08-11 주식회사 엘지생활건강 구강질환 예방 또는 치료용 조성물
CN108434017A (zh) * 2018-06-13 2018-08-24 长沙小如信息科技有限公司 一种牙齿美白液及其制备方法
WO2021081634A1 (en) * 2019-10-28 2021-05-06 Kieran Murphy Formulation to reduce or prevent oxidative stress damage
CN113367337B (zh) * 2020-03-10 2023-02-24 晨光生物科技集团股份有限公司 一种包含槲皮万寿菊素的组合物
CN111700888A (zh) * 2020-06-18 2020-09-25 中国医学科学院放射医学研究所 一种漆黄素及其盐在制备抗辐射损伤药物中的应用
CN111728966A (zh) * 2020-07-07 2020-10-02 苏州大学 Egcg在制备电离辐射致肠道损伤的防护药物中的应用
CN112716854B (zh) * 2021-01-27 2022-12-13 新乡博凯生物技术有限公司 一种中药牙膏及其制备方法
ES2956376A1 (es) * 2022-05-13 2023-12-20 Espada Regalado Jesus Uso de un procedimiento de transferencia fotonica secuencial para fomentar la fotoproteccion y regeneracion cutanea
CN115364016B (zh) * 2022-09-27 2023-07-25 云南八凯生物科技有限公司 一种具有改善牙周病功效的牙膏及其制备方法
CN116492320B (zh) * 2023-06-27 2023-09-29 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 大果桉醛i在制备肿瘤免疫治疗增效剂中的应用
KR102915228B1 (ko) 2023-09-04 2026-01-22 한국원자력연구원 방사선 에너지 강하용 조성물 및 이를 이용한 코팅층을 갖는 태양전지
CN119970694A (zh) * 2025-03-12 2025-05-13 中国科学院近代物理研究所 姜黄素在制备预防和/或治疗Ra-223引起的骨组织辐射损伤的药物中的应用
CN120131626B (zh) * 2025-05-16 2025-07-22 台州恩泽医疗中心(集团) 金合欢素和辅酶q10组合物在防治阿霉素诱导心肌毒性的药物中的应用

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147795A (en) * 1977-02-11 1979-04-03 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4250097A (en) * 1978-03-08 1981-02-10 Syntex (U.S.A.) Inc. Compositions for and a method of preventing diabetic complications
US4232040A (en) * 1978-03-08 1980-11-04 Syntex (U.S.A.) Inc. Compositions for and a method of preventing diabetic complications
US4210667A (en) * 1979-04-19 1980-07-01 Pfizer Inc. Pharmaceutical preparations containing coumarin carboxylic acid derivatives
JPS60100517A (ja) * 1983-11-08 1985-06-04 Eisai Co Ltd 放射線潰瘍治療剤および方法
US4627973A (en) * 1984-12-14 1986-12-09 Charles Of The Ritz Group Ltd. Skin mousse
WO1993013092A1 (en) * 1986-11-24 1993-07-08 Reinhard Sarges Imidazolidinedione derivatives
US4822816A (en) * 1987-04-10 1989-04-18 Oxycal Laboratories, Inc. Compositions and methods for administering vitamin C
US5070085A (en) * 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
FR2675996B1 (fr) * 1991-04-30 1993-10-15 Georges Baritiu Compositions sanogenes dietetiques complexes.
KR930008763B1 (ko) * 1991-05-27 1993-09-15 주식회사 태평양화학 화장료 조성물
US5561110A (en) * 1991-09-09 1996-10-01 Peptide Technology Limited Method for the treatment of the complications and pathology of diabetes
IT1254045B (it) * 1991-12-31 1995-09-06 Lifegroup Spa Derivati idrosolubili della biotina e relative composizioni terapeutiche
GB9206648D0 (en) * 1992-03-26 1992-05-06 Leo Pharm Prod Ltd Chemical compounds
US5728704A (en) * 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
US5298525A (en) * 1992-11-23 1994-03-29 University Technologies International, Inc. Diabetes prevention and treatment
FR2699818B1 (fr) * 1992-12-24 1995-02-03 Oreal Composition cosmétique ou pharmaceutique contenant en association un polyphénol et un extrait de gingko.
US5665360A (en) * 1993-05-14 1997-09-09 Mann; Richard H. Method of treating peripheral neuropathies of the feet and legs
GB9315253D0 (en) * 1993-07-23 1993-09-08 Res Inst Medicine Chem Chemical compounds
JP2790163B2 (ja) * 1993-07-29 1998-08-27 富士通株式会社 シリコン酸化膜の形成方法、半導体装置の製造方法及びフラットディスプレイ装置の製造方法
CZ267396A3 (en) * 1994-03-11 1997-03-12 Procter & Gamble HYDROLYTIC STABLE COSMETIC, PREPARATION WITH LOW pH VALUE CONTAINING ACID ACTIVE SUBSTANCES
US5595982A (en) * 1994-03-31 1997-01-21 Harlmen Inc. Equine nutritional supplement
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
ATE223202T1 (de) * 1994-09-30 2002-09-15 Mika Pharma Ges Fuer Die Entwi Pharmazeutische zusammensetzung
US5571441A (en) * 1994-11-01 1996-11-05 The Procter & Gamble Company Nutrient supplement compositions providing physiologic feedback
US5648083A (en) * 1995-02-10 1997-07-15 The Procter & Gamble Company Personal care compositions and wipe products containing the compositions
US5614224A (en) * 1995-04-20 1997-03-25 Womack; Rick W. Nutritional supplement for diabetics
CA2244535A1 (en) * 1995-05-15 2000-01-30 Avon Products, Inc. Novel uses for ascorbyl-phosphoryl-cholesterol in topical compositions
KR100192678B1 (ko) * 1995-06-07 1999-06-15 손경식 약효가 증강된 가공인삼 제품
US5709868A (en) * 1995-09-20 1998-01-20 Perricone; Nicholas V. Lipoic acid in topical compositions
US6162801A (en) * 1995-11-20 2000-12-19 Kita; Kiyoshi External ophthalmic preparation containing vitamin D
US5948443A (en) * 1996-02-23 1999-09-07 Medical Doctor's Research Institute, Inc. Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease
US5998393A (en) * 1996-04-05 1999-12-07 Kang; Sewon Methods for assessing 1,25(OH)2 D3 activity in skin and for enhancing the therapeutic use of 1,25(OH)2 D3
DE19615577A1 (de) * 1996-04-19 1997-10-23 Beiersdorf Ag Verwendung von Salicin als antiirritativer Wirkstoff in kosmetischen und topischen dermatologischen Zubereitungen
US5895652A (en) * 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
US5840736A (en) * 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5804594A (en) * 1997-01-22 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for improving wrinkles and other skin conditions
US5804168A (en) * 1997-01-29 1998-09-08 Murad; Howard Pharmaceutical compositions and methods for protecting and treating sun damaged skin
US5976568A (en) * 1997-02-21 1999-11-02 Medical Doctors' Research Institute, Inc. Modular system of dietary supplement compositions for optimizing health benefits and methods
US5962030A (en) * 1997-03-07 1999-10-05 Akesis Pharmaceuticals, Inc. Dietary supplement and method of treatment for diabetic control
JPH10251146A (ja) * 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
US5883086A (en) * 1997-05-02 1999-03-16 Craft; John C. DHEA-containing nutritional supplement
US6207656B1 (en) * 1997-05-22 2001-03-27 Cephalon, Inc. Vitamin D analogues and their neuronal effects
US5972359A (en) * 1997-05-23 1999-10-26 The Procter & Gamble Company Skin care compositions and method of improving skin appearance
US5976579A (en) * 1997-07-03 1999-11-02 Mclean; Linsey Nutritional supplement for the prevention and treatment of excessive intestinal permeability
US6054128A (en) * 1997-09-29 2000-04-25 Wakat; Diane Dietary supplements for the cardiovascular system
DE19755504A1 (de) * 1997-12-13 1999-06-17 Beiersdorf Ag Verwendung von Flavonen und Flavonoiden gegen die UV-induzierte Zersetzung von Dibenzoylmethan und dessen Derivaten
BR9908870A (pt) * 1998-03-16 2000-11-21 Procter & Gamble Processos para regularizarem a aparência da pele
JP2002519312A (ja) * 1998-06-30 2002-07-02 エイボン プロダクツ インコーポレーテッド 皮膚美白組成物
US6048886A (en) * 1998-10-05 2000-04-11 Neigut; Stanley Compositions and delivery systems for the topical treatment of psoriasis and other conditions of the skin
US6296861B1 (en) * 1999-05-03 2001-10-02 Nicholas V. Perricone Treatment of skin damage using conjugated linoleic acid and ascorbyl fatty acid esters
HK1050840A1 (zh) * 1999-11-24 2003-07-11 Access Business Group International Llc 局部使用皮肤组合物
US6299896B1 (en) * 2000-04-13 2001-10-09 Cooper Concepts, Inc. Multi-vitamin and mineral supplement
US6555573B2 (en) * 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
NZ526041A (en) * 2000-12-21 2005-01-28 The Quigley Corp Method and composition for the treatment of diabetic neuropathy
US6592896B2 (en) * 2001-08-06 2003-07-15 The Quigley Corporation Medicinal composition and method of using it
US6596313B2 (en) * 2001-08-06 2003-07-22 The Quigley Corporation Nutritional supplement and methods of using it

Also Published As

Publication number Publication date
WO2003051287A3 (en) 2005-04-14
EP1536801A2 (en) 2005-06-08
CN1635907A (zh) 2005-07-06
EP1505984A4 (en) 2006-10-25
MXPA04004377A (es) 2004-08-11
JP2005510509A (ja) 2005-04-21
AU2002309615B2 (en) 2007-10-18
JP2005528333A (ja) 2005-09-22
CA2465945A1 (en) 2003-05-15
WO2003051287A2 (en) 2003-06-26
MXPA04004376A (es) 2004-08-11
CN1630521A (zh) 2005-06-22
IL161775A0 (en) 2005-11-20
WO2003039452A2 (en) 2003-05-15
CA2465888A1 (en) 2003-06-26
AU2002365155B2 (en) 2007-10-18
WO2003039452A3 (en) 2004-12-02
EP1505984A2 (en) 2005-02-16
AU2002365155A1 (en) 2003-06-30
NZ532774A (en) 2008-08-29
NZ532775A (en) 2006-10-27
EP1536801A4 (en) 2006-10-25
US20030105027A1 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
IL161774A0 (en) Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
ZA200403364B (en) Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
GB0118394D0 (en) Radiation treatment system and method
AU2003290548A8 (en) Prevention and treatment of synucleinopathic disease
AU2003256253A8 (en) Aerosol for medical treatment and methods
ZA200107315B (en) Pharmaceutical combinations for the treatment of stroke and traumatic brain injury.
IL165950A0 (en) Compositions and method for the diagnosis and treatment of tumor
TWI347188B (en) Treatment and prevention of osteoporosis
HUP0400231A3 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
HUP0401808A3 (en) Dosage forms, devices and methods of treatment
ZA200500749B (en) Nutritional composition for detoxification and cancer prevention
EG25067A (en) Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals.
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
EP1461047A4 (en) COMPOSITIONS AND METHODS FOR TREATING ANIMALS
IL145397A0 (en) Compositions and methods for treatment of cancer
GB0108671D0 (en) Skin treatment
PL368035A1 (en) Compositions and methods for the treatment of cancer
HUP0401913A3 (en) Medicine for preventing and treating bromhidrosis
GB0115707D0 (en) Treatment and prevention of lipodermatosclerosis
AU2002349268A1 (en) Medicine for preventing and treating bromidrosis
EP1472273A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES
IL166062A0 (en) Compositions and methods for therapeutic treatment
HUP0303303A3 (en) Treatment bed, treatment apparatus and treatment device
AU2002330724A1 (en) Diagnosis, prevention and treatment of cancer